



June 1, 2017

## Aerie Pharmaceuticals to Present at Two Investor Conferences in June

IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, and Richard Rubino, Chief Financial Officer, will attend the following conferences in June.

- | Jefferies 2017 Healthcare Conference
  - | Presentation Date: Tuesday, June 6, 2017
  - | Presentation Time: 10:30am E.T.
  - | Location: New York, NY
- | JMP Securities Life Science Conference 2017
  - | Presentation Date: Tuesday, June 20, 2017
  - | Presentation Time: 11:30am E.T.
  - | Location: New York, NY

The presentations will be webcast live and may be accessed by visiting Aerie's website at <http://investors.aeriepharma.com/>. A replay of each webcast will be available for 10 business days.

### About Aerie Pharmaceuticals, Inc.

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two current product candidates are once-daily intraocular pressure-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA (new drug application) for Rhopressa<sup>TM</sup> (netarsudil ophthalmic solution) 0.02% was submitted to the U.S. Food and Drug Administration (FDA) in February 2017, and, in May 2017, the FDA set the PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA's review of the Rhopressa<sup>TM</sup> NDA for February 28, 2018. Aerie's second product candidate, Roclatan<sup>TM</sup> (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of Rhopressa<sup>TM</sup> and widely prescribed PGA latanoprost, achieved its primary efficacy endpoint in two Phase 3 registration trials, named Mercury 1, which is still ongoing, and Mercury 2. A Roclatan<sup>TM</sup> NDA submission is expected to take place in the first half of 2018. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20170601005038/en/): <http://www.businesswire.com/news/home/20170601005038/en/>

Aerie Pharmaceuticals  
Richard Rubino, 908-947-3540  
[r rubino@aeriepharma.com](mailto:r rubino@aeriepharma.com)

or  
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals  
Ami Bavishi, 212-213-0006  
[abavishi@burnsmc.com](mailto:abavishi@burnsmc.com)

Source: Aerie Pharmaceuticals, Inc.

News Provided by Acquire Media